Juan-Miguel Guerras1,2, Patricia García de Olalla2,3, María José Belza4,5, Luis de la Fuente1,2, David Palma2,3, Jorge Del Romero6, Jorge-Néstor García-Pérez7, Juan Hoyos8. 1. Centro Nacional de Epidemiología, Instituto de Salud Carlos III, Madrid, Spain. 2. CIBER Epidemiologia Y Salud Pública (CIBERESP), Madrid, Spain. 3. Servicio de Epidemiología, Agència de Salut Pública de Barcelona, Barcelona, Spain. 4. CIBER Epidemiologia Y Salud Pública (CIBERESP), Madrid, Spain. mbelza@isciii.es. 5. Escuela Nacional de Sanidad, Instituto de Salud Carlos III, Monforte de Lemos 5, 28029, Madrid, Spain. mbelza@isciii.es. 6. Centro Sanitario Sandoval, Instituto de Investigación Sanitaria San Carlos, Hospital Clínico San Carlos, Madrid, Spain. 7. Unidad de ITS de Vall D'Hebron-Drassanes, Hospital Vall D'Hebron, Barcelona, Spain. 8. Departamento de Salud Pública Y Materno-Infantil, Universidad Complutense de Madrid, Madrid, Spain.
Abstract
BACKGROUND: We estimate the prevalence of drug injection, the variables associated with having ever injected and the proportion of ever injectors whose first drug injection was for having sex; we describe the first drug injection episode, analyze the drugs most frequently injected and estimate the prevalence of risky injecting behaviors. METHODS: The participants were 3387 MSM without a previous HIV diagnosis attending four HIV/STI diagnosis services in Madrid and Barcelona. Lifetime prevalence and prevalence ratios (PRs) by different factors were calculated using Poisson regression models with robust variance. We compared the characteristics of first drug injection episode, lifetime injection and risky injecting behaviors of those whose first injection was for sex (FIS) with those whose was not (non-FIS). RESULTS: Lifetime prevalence of injection was 2.1% (CI 1.7-2.7). In the multivariate analysis, it was strongly associated with having been penetrated by more than five men in the last 12 months (aPR = 10.4; CI 2.5-43.4) and having met most of their partners at private parties (aPR = 7.5; CI 4.5-12.3), and less strongly with other factors. Of those who had ever injected drugs, 81.9% injected for sex the first time they injected drugs (FIS). At first injection, FIS participants had a mean age of 31 years, 62.7% used mephedrone and 32.2% methamphetamine on that occasion. Of this FIS group 39.0% had ever shared drugs or equipment and 82.6% had always shared for sex. Some 30.8% of non-FIS reported having also injected drugs for sex later on. CONCLUSIONS: Only two out of a hundred had ever injected, most to have sex and with frequent drug or injecting equipment sharing. Injecting for sex is the most common first episode of drug injection and is the most efficient risky behavior for the transmission of HIV, hepatitis B or C and other blood-borne infections. MSM participating in private parties should be considered a priority group for prevention policies.
BACKGROUND: We estimate the prevalence of drug injection, the variables associated with having ever injected and the proportion of ever injectors whose first drug injection was for having sex; we describe the first drug injection episode, analyze the drugs most frequently injected and estimate the prevalence of risky injecting behaviors. METHODS: The participants were 3387 MSM without a previous HIV diagnosis attending four HIV/STI diagnosis services in Madrid and Barcelona. Lifetime prevalence and prevalence ratios (PRs) by different factors were calculated using Poisson regression models with robust variance. We compared the characteristics of first drug injection episode, lifetime injection and risky injecting behaviors of those whose first injection was for sex (FIS) with those whose was not (non-FIS). RESULTS: Lifetime prevalence of injection was 2.1% (CI 1.7-2.7). In the multivariate analysis, it was strongly associated with having been penetrated by more than five men in the last 12 months (aPR = 10.4; CI 2.5-43.4) and having met most of their partners at private parties (aPR = 7.5; CI 4.5-12.3), and less strongly with other factors. Of those who had ever injected drugs, 81.9% injected for sex the first time they injected drugs (FIS). At first injection, FISparticipants had a mean age of 31 years, 62.7% used mephedrone and 32.2% methamphetamine on that occasion. Of this FIS group 39.0% had ever shared drugs or equipment and 82.6% had always shared for sex. Some 30.8% of non-FIS reported having also injected drugs for sex later on. CONCLUSIONS: Only two out of a hundred had ever injected, most to have sex and with frequent drug or injecting equipment sharing. Injecting for sex is the most common first episode of drug injection and is the most efficient risky behavior for the transmission of HIV, hepatitis B or C and other blood-borne infections. MSM participating in private parties should be considered a priority group for prevention policies.
Authors: Luis de la Fuente; María José Bravo; Carlos Toro; M Teresa Brugal; Gregorio Barrio; Vicente Soriano; Fernando Vallejo; Rosario Ballesta Journal: J Epidemiol Community Health Date: 2006-06 Impact factor: 3.710
Authors: Alicia González-Baeza; Helen Dolengevich-Segal; Ignacio Pérez-Valero; Alfonso Cabello; María Jesús Téllez; José Sanz; Leire Pérez-Latorre; José Ignacio Bernardino; Jesús Troya; Sara De La Fuente; Otilia Bisbal; Ignacio Santos; Sari Arponen; Víctor Hontañon; José Luis Casado; Pablo Ryan Journal: AIDS Patient Care STDS Date: 2018-03 Impact factor: 5.078
Authors: Philippe Trouiller; Annie Velter; Leïla Saboni; Cécile Sommen; Claire Sauvage; Sophie Vaux; Francis Barin; Stéphane Chevaliez; Florence Lot; Marie Jauffret-Roustide Journal: Int J Drug Policy Date: 2020-04-04
Authors: B Hampel; K Kusejko; R D Kouyos; J Böni; M Flepp; M Stöckle; A Conen; C Béguelin; P Künzler-Heule; D Nicca; A J Schmidt; H Nguyen; J Delaloye; M Rougemont; E Bernasconi; A Rauch; H F Günthard; D L Braun; J Fehr Journal: HIV Med Date: 2019-12-18 Impact factor: 3.180
Authors: Juan-Miguel Guerras; Juan Hoyos; Cristina Agustí; Jordi Casabona; Luis Sordo; José Pulido; Luis De la Fuente; María-José Belza; Grupo de Trabajo Euro Hiv Edat Journal: Adicciones Date: 2022-02-16 Impact factor: 2.979